Psoriasis in skin of color is often overlooked because of differences in its presentation. Hear from Dr. Amy McMichael as she explains diagnostic challenges and shares therapeutic strategies for this patient population. Dr. McMichael is a Professor of Dermatology at Wake Forest University School of Medicine in Winston-Salem, North Carolina.
Chronic hand eczema is a persistent and often multifactorial condition that poses substantial challenges for both patients and clinicians. To help clinicians overcome these challenges, U.S. and international guidelines are evolving to better direct the diagnosis and treatment of chronic hand eczema, especially given the recent FDA approval of delgocitinib. Joining Dr. Charles Turck to review the latest guidelines and how we can use them in clinical practice is Dr. Raj Chovatiya. He's an Associate Professor at the Rosalind Franklin University Chicago Medical School as well as the Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.
The DELTA 1 and DELTA 2 trials examined the efficacy and safety of the topical pan-JAK inhibitor delgocitinib in patients with moderate to severe chronic hand eczema. Based on the findings, no new safety signals were observed, and nearly half of patients achieved a 75 percent improvement in HECSI scores as well as meaningful relief in itch, pain, and quality of life. Here to talk about the trials’ design and findings—as well as his own firsthand experience treating patients who were enrolled in the trials—is board-certified dermatologist Dr. Robert Bissonnette.
Chronic hand eczema presents persistent challenges, often driven by overlapping etiologies that complicate diagnosis and management. But by applying the latest guidelines, we can optimize both short- and long-term outcomes for our patients. Here with Dr. Raj Chovatiya to share a real-world patient case that highlights diagnostic and treatment strategies is Dr. Benjamin Ehst. Not only is he a board-certified dermatologist with a doctorate in immunology, but he's also an investigator at the Oregon Medical Research Center and dermatologist at the Broadway Medical Clinic in Portland, Oregon.
Head and neck involvement in atopic dermatitis significantly affects patients’ daily lives, often driving greater stigma, discomfort, and disease severity. Given this region’s impact, a post hoc analysis of the ECZTRA 1 and 2 and ECZTEND trials examined tralokinumab and found that this IL-13 inhibitor not only provided sustained reductions in head and neck EASI scores, but patients also reported better Dermatology Life Quality Index scores. Tune in to hear Dr. Raj Chovatiya dive further into the findings and their potential implications for atopic dermatitis care. Dr. Chovatiya is an Associate Professor at the Rosalind Franklin University Chicago Medical School, as well as the Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.
Combined dermatology–rheumatology clinics are transforming psoriatic disease care by streamlining communication, reducing patient burden, and enabling more targeted, effective treatments. To learn more about how these clinks work and why they matter for patients with psoriatic disease, tune in to hear from Dr. Eric Ruderman, Professor of Medicine and the Associate Chief of Clinical Affairs for the Division of Rheumatology at Northwestern University Feinberg School of Medicine.
Sebopsoriasis—where features of seborrheic dermatitis and psoriasis converge—remains a diagnostic gray area in dermatology. In this expert-led discussion, Dr. Raj Chovatiya explores the clinical nuances, distinguishing features, and immunologic overlap of these conditions. Dr. Chovatiya is a Clinical Associate Professor at the Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research.
Seborrheic dermatitis and psoriasis often overlap in presentation and location, making accurate diagnosis and effective treatment essential. Hear from Dr. Raj Chovatiya as he shares the latest evidence on non-steroidal therapies, addresses limitations of traditional treatments, and offers practical guidance for managing special sites and mixed presentations. Dr. Chovatiya is a Clinical Associate Professor at the Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research.
Explore the latest breakthroughs in dermatology care with Dr. James Del Rosso, who highlights newly approved and emerging therapies for severe alopecia area, actinic keratosis, and atopic dermatitis. Dr. Del Rosso is the Research Director at JDR Dermatology Research, an Adjunct Clinical Professor of Dermatology at Touro University Nevada, and a practicing dermatologist in Las Vegas. He also presented on this topic at the 2025 Fall Clinical Dermatology Conference for Physician Assistants and Nurse Practitioners.
To ensure comprehensive care for atopic dermatitis, it’s essential to be aware of cultural differences and barriers to care in underserved populations. Dr. Ruchi Gupta, a Professor of Pediatrics and Medicine at Northwestern University Feinberg School of Medicine, highlights the need for increased awareness and collaboration between generalists and dermatologists to ensure better atopic dermatitis care.
Limited education, research, and access to care contribute to disparities in atopic dermatitis care among diverse populations. Hear from Dr. Ruchi Gupta, a Professor of Pediatrics and Medicine at Northwestern University Feinberg School of Medicine, as she discusses gaps in care among different racial and ethnic groups.
Pregnancy can trigger atopic dermatitis, with immune system shifts commonly contributing to skin issues. Dr. Jennifer Murase joins the program to explain the mechanisms behind pregnancy dermatoses and best practices for caring for patients, which she presented on at the 2024 Elevate Derm Conference. Dr. Murase is the Founder and Chair of the American Academy of Dermatology Women’s Health Expert Resource Group.
Patients’ adherence to psoriasis treatment, especially topical treatment, is often abysmal due to a variety of challenges and factors. That’s why Dr. Charles Turck speaks with Dr. Steven Feldman about these common challenges and how we can overcome them to improve adherence among our psoriasis patients. Dr. Feldman is a Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston Salem, North Carolina.
It’s not uncommon for patients with inflammatory bowel disease (IBD) to have an overlapping immune-mediated condition like psoriasis, which is why it’s important to tailor therapy for these patients. Here to discuss the link between psoriasis and IBD and how this can affect our management approach is Dr. Andres Yarur, Associate Professor of Medicine at Cedars Sinai Medical Center in Los Angeles, California.
This study assessed the link between depressive symptoms in real-world patients with psoriasis to help identify characteristics for those at risk. What were the findings? To learn more, join Dr. Charles Turck as he speaks with Dr. Neda Shahriari, Board-Certified Dermatologist at Brigham and Women’s Hospital in Boston, Massachusetts.
The biologics we know are revolutionary treatments for our patients with psoriasis and now other inflammatory skin diseases. So how do biosimilars play a part in the evolving treatment of psoriasis? Learn more with Dr. Raj Chovatiya as he dives further into biosimilars with Dr. Steve Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.
Two of the biggest trials were recently completed for the use of IL-17 inhibitors for treating hidradenitis suppurativa (HS). So what data should we know about? In this episode, Dr. Raj Chovatiya is joined by Dr. Martina Porter, Dermatologist at Beth Israel Deaconess Medical Center and Assistant Professor of Dermatology at Harvard Medical School.
For patients with hidradenitis suppurativa (HS), the exact cause of the condition is still being researched. So what therapies are currently available to treat this painful condition? To discuss what you need to know, Dr. Raj Chovatiya is joined by Dr. Martina Porter, Dermatologist at Beth Israel Deaconess Medical Center and Assistant Professor of Dermatology at Harvard Medical School.
The future looks promising for alopecia areata patients as two JAK inhibitors have been tested in clinical trials while other treatment studies are ongoing. So what should clinicians know about these therapies? Learn more as Dr. Raj Chovatiya speaks to Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist with Dermatology Physicians of Connecticut.
Initially approved for the treatment of rheumatoid arthritis, baricitinib is now the first FDA-approved treatment for patients with alopecia areata. So what can patients look forward to with this new therapy? Dive in with Dr. Raj Chovatiya as he’s joined by Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist at Dermatology Physicians of Connecticut.